Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2010-05-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted to Intensive Care Unit
NCT05671159
Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?
NCT01653665
The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis
NCT01649921
Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock
NCT00252915
GM-CSF to Decrease ICU Acquired Infections
NCT02361528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Primary objective: To determine the innate immune functions of immature neutrophils in comparison to those from mature neutrophils, sampled from patients with severe sepsis and sepsis shock and in control patients (trauma patients and healthy donors (only mature neutrophils in the latter case)
2. Secondary objectives: To determine the fate and span life of immature neutrophils in comparison to mature neutrophils, sampled from patients with severe sepsis and sepsis shock and in control patients (trauma patients and healthy donors (only mature neutrophils in the latter case).
Inclusion criteria
* Patients with severe sepsis or septic shock (according to ACCP/FCCM standard definitions) with \> 5% immature neutrophils.
* Patients with a noninfectious systemic inflammatory response syndrome (SIRS), e.g. patients with head trauma or multiple trauma with \> 5% immature neutrophils.
* Healthy donors
Exclusion criteria
* Severe immunosuppression (e.g. HIV with \< 200 CD4/mm3), treatment with glucocorticoids (\> 300 mg hydrocortisone/day) or other immunosuppressive therapy
* Neutropenia (neutrophils \< 0.5 G/l).
* Recent chemotherapy or administration of intravenous immunoglobulins within the last 4 weeks.
Endpoints
* Surface expression of receptors of the innate immunity in immature vs. mature neutrophils.
* Production by immature vs. mature neutrophils of inflammatory mediators and reactive oxygen species in response to bacterial agonists.
* Chemotaxis of immature vs. mature neutrophils.
* Phagocytosis of Gram-positive and Gram-negative bacteria by immature vs. mature neutrophils.
* Ex vivo viability and resistance to apoptosis of immature vs. mature neutrophils.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sepsis patients
Patients presenting sepsis
No interventions assigned to this group
SIRS patients
Patients presenting with the systemic inflammatory response syndrome
No interventions assigned to this group
Healthy subjects
Healthy blood donors
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a noninfectious systemic inflammatory response syndrome (SIRS), e.g. patients with head trauma or multiple trauma with \> 5% immature neutrophils.
* Healthy donors
Exclusion Criteria
* Neutropenia (neutrophils \< 0.5 G/l).
* Recent chemotherapy or administration of intravenous immunoglobulins within the last 4 weeks.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospitals of Geneva
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals of Geneva, Intensive Care
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CER 09-311
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.